OverviewSuggest Edit

Sosei Heptares is an international biopharmaceutical company focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR technology and structure-based drug design platform capabilities. The Company aims to advance a broad and deep pipeline of partnered and wholly owned product candidates in multiple therapeutic areas, including CNS, cancer, metabolic diseases and other rare/specialty indications.

TypePublic
Founded1990
HQChiyoda City, JP
Websitesoseiheptares.com

Latest Updates

Employees (est.) (Sept 2020)170(+5%)
Share Price (Sept 2020)¥1.4 K
Cybersecurity ratingAMore

Key People/Management at Sosei Heptares

Chris Cargill

Chris Cargill

Executive Vice President, Chief Financial Officer
Shinichi Tamura

Shinichi Tamura

Chairman of the Board, Representative Executive Officer, Chairman, President and Chief Executive Officer
Barry Kenny

Barry Kenny

Chief Business Officer, Business Development
Kazuhiko Yoshizumi

Kazuhiko Yoshizumi

Executive Vice President, Group Chief Compliance Officer
Malcolm Weir

Malcolm Weir

Executive Vice Chairman
Miles Congreve

Miles Congreve

Chief Scientific Officer
Show more

Sosei Heptares Office Locations

Sosei Heptares has offices in Chiyoda City, Great Abington and London
Chiyoda City, JP (HQ)
2-1 Kojimachi
Great Abington, GB
Granta Park
London, GB
119 Marylebone Road North West House
Show all (3)

Sosei Heptares Financials and Metrics

Sosei Heptares Revenue

Market capitalization (14-Sept-2020)

113.0b

Closing stock price (14-Sept-2020)

1.4k
Sosei Heptares's current market capitalization is ¥113 b.
Show all financial metrics

Sosei Heptares Acquisitions / Subsidiaries

Company NameDateDeal Size
Heptares TherapeuticsFebruary 22, 2015$400 m

Sosei Heptares Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Sosei Heptares Online and Social Media Presence

Embed Graph

Sosei Heptares News and Updates

Sosei Heptares Operational Highlights and Consolidated Results for the First Half 2020

TOKYO and LONDON, Aug. 13, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results for the first half ended 30 June 2020. The full report can be accessed by clicking here. Operational...

Sosei Heptares Successfully Raises US$200 million in International Offering of New Shares and Convertible Bonds

TOKYO and LONDON, July 16, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) today announces the successful completion of an International Offering of new shares and euro-yen denominated convertible bonds due 2025 that has raised a total of approximately $200...

Sosei Heptares Notes Phase IIIb ARGON Study With Enerzair® Breezhaler® (QVM149) Meets Primary Endpoint in Patients With Uncontrolled Asthma

TOKYO and LONDON, June 5, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) notes that its strategic alliance partner Novartis has announced that full results from the Phase IIIb ARGON study were published online in Respiratory Medicine.1 The Phase IIIb open label...

Sosei Heptares to Apply its Structure-based Drug Design Expertise in New COVID-19 R&D Program

TOKYO and LONDON, April 14, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) today announces it will apply its unique structure-based drug design platform and capabilities to the global research efforts to discover drugs targeting the SARS-CoV-2 coronavirus and to...

Sosei Heptares Operational Highlights and Consolidated Results for the 12 Months Ended 31 December 2019

TOKYO and LONDON, Feb. 13, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results for the twelve months ended 31 December 2019. The full report can be accessed by clicking here. Operational...

Sosei Heptares Announces the First Phase I Clinical Start From Its Multi-target Drug Discovery Collaboration With Pfizer

TOKYO and LONDON, Dec. 23, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) has been notified by its strategic alliance partner Pfizer that it has dosed the first subject in a clinical trial with a new drug candidate nominated from the multi-target drug discovery...
Show more

Sosei Heptares Frequently Asked Questions

  • When was Sosei Heptares founded?

    Sosei Heptares was founded in 1990.

  • Who are Sosei Heptares key executives?

    Sosei Heptares's key executives are Chris Cargill, Shinichi Tamura and Barry Kenny.

  • How many employees does Sosei Heptares have?

    Sosei Heptares has 170 employees.

  • Who are Sosei Heptares competitors?

    Competitors of Sosei Heptares include LEO Pharma, Imara and Tanvex Biopharma.

  • Where is Sosei Heptares headquarters?

    Sosei Heptares headquarters is located at 2-1 Kojimachi, Chiyoda City.

  • Where are Sosei Heptares offices?

    Sosei Heptares has offices in Chiyoda City, Great Abington and London.

  • How many offices does Sosei Heptares have?

    Sosei Heptares has 3 offices.